©The Author(s) 2025.
World J Gastroenterol. Sep 21, 2025; 31(35): 110152
Published online Sep 21, 2025. doi: 10.3748/wjg.v31.i35.110152
Published online Sep 21, 2025. doi: 10.3748/wjg.v31.i35.110152
Table 2 Survival and local control outcomes in colorectal cancer patients with lung metastases stratified by treatment modalities
| All patients (n = 247) | Only RFA (n = 99) | Combined (n = 148) | |
| OS (%) | |||
| 1-year | 99.1 | 97.9 | 99.2 |
| 3-year | 95.4 | 94.7 | 95.9 |
| 5-year | 80.0 | 69.1 | 88.7 |
| PFS (%) | |||
| 1-year | 81.8 | 79.8 | 83.1 |
| 3-year | 43.4 | 38.4 | 46.8 |
| 5-year | 26.2 | 23.7 | 27.8 |
| LTP (%) | |||
| 1-year | 3.2 | 5.1 | 2.0 |
| 3-year | 18.2 | 28.8 | 10.9 |
| 5-year | 33.8 | 49.0 | 22.7 |
- Citation: Li KN, Ying LL, Du N, Wang Y, Huang HZ, Wang YH, Xu LC, Zhao Q, Song G, Hu YB, Li WT, Yan Y, Chen C, He XH. Radiofrequency ablation with or without capecitabine maintenance therapy for lung oligometastases from colorectal cancer. World J Gastroenterol 2025; 31(35): 110152
- URL: https://www.wjgnet.com/1007-9327/full/v31/i35/110152.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i35.110152